Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma (NASDAQ: TBPH) will host a virtual key opinion leader investor event on December 8, 2025 at 10:30 AM ET to review ampreloxetine's Phase 3 clinical development program for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) ahead of topline data expected in Q1 2026. The session will feature Horacio Kaufmann, MD, and company management discussing the unmet medical need in MSA, the CYPRESS Phase 3 study design informed by positive REDWOOD results, and ampreloxetine's commercial opportunity and strategy. A live Q&A will follow.
Theravance Biopharma (NASDAQ: TBPH) will host a virtual key opinion leader investor event on December 8, 2025 at 10:30 AM ET to review ampreloxetine's Phase 3 clinical development program for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) ahead of topline data expected in Q1 2026. The session will feature Horacio Kaufmann, MD, and company management discussing the unmet medical need in MSA, the CYPRESS Phase 3 study design informed by positive REDWOOD results, and ampreloxetine's commercial opportunity and strategy. A live Q&A will follow.
Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.
Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 results on Nov 10, 2025: YUPELRI U.S. net sales hit a record $71.4M (+15% YoY) and brand profitability improved. The company achieved non-GAAP breakeven in Q3 and ended September 30 with $332.7M cash and no debt. Enrollment in the pivotal Phase 3 CYPRESS trial of ampreloxetine is complete; the open-label portion finished and topline readout is expected in Q1 2026, with plans to prepare an expedited NDA and request priority review if supportive. TRELEGY global sales trends are on track to trigger milestone payments from Royalty Pharma if required sales levels are met in Q4 2025. A virtual KOL investor event on ampreloxetine is scheduled for Dec 8, 2025.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 results on Nov 10, 2025: YUPELRI U.S. net sales hit a record $71.4M (+15% YoY) and brand profitability improved. The company achieved non-GAAP breakeven in Q3 and ended September 30 with $332.7M cash and no debt. Enrollment in the pivotal Phase 3 CYPRESS trial of ampreloxetine is complete; the open-label portion finished and topline readout is expected in Q1 2026, with plans to prepare an expedited NDA and request priority review if supportive. TRELEGY global sales trends are on track to trigger milestone payments from Royalty Pharma if required sales levels are met in Q4 2025. A virtual KOL investor event on ampreloxetine is scheduled for Dec 8, 2025.
Theravance Biopharma (NASDAQ: TBPH) will present four ampreloxetine presentations at the 36th International Symposium on the Autonomic Nervous System, Nov 5-8, 2025, in Clearwater Beach, FL.
One platform presentation on precision therapy in multiple system atrophy (MSA) will be given on Nov 8, 2025 at 8:30 am ET. Three posters on supine hypertension, retention strategies, and enrollment strategies will be presented on Nov 6, 2025 at 7:00-8:30 pm ET. Topline results from the ongoing Phase 3 CYPRESS study are anticipated in Q1 2026.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. A conference call and simultaneous webcast are scheduled for 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) that day.
Investors may join the live call by telephone with pre-registration or listen via the live audio webcast on the company’s Investors Events and Presentation page. A replay of the webcast will be available on the company website through December 10, 2025.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. A conference call and simultaneous webcast are scheduled for 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) that day.
Investors may join the live call by telephone with pre-registration or listen via the live audio webcast on the company’s Investors Events and Presentation page. A replay of the webcast will be available on the company website through December 10, 2025.
Theravance Biopharma (NASDAQ: TBPH) launched “Power in the Periphery,” a disease education campaign for healthcare professionals to raise awareness of neurogenic orthostatic hypotension (nOH) in Multiple System Atrophy (MSA).
The initiative was introduced at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Honolulu, October 5–9, 2025, and aims to deepen scientific understanding of nOH pathophysiology in MSA and improve clinician engagement. nOH symptoms include lightheadedness, fainting, fatigue, blurry vision, weakness, concentration problems, and head/neck pain. Theravance directs clinicians to www.nOHUncovered.com for educational resources.
FAQ
What is the current stock price of Theravance Bioph (TBPH)?
What is the market cap of Theravance Bioph (TBPH)?
